About
Hydrogel depot technology for sustained ocular drug delivery. Axpaxli (axitinib intravitreal implant) in late-stage trials for wet AMD; Dextenza commercial for ocular surgery/post-op.
HQ: Bedford, MA, USA
Funding
Public (NASDAQ: OCUL)
—Company profile
Hydrogel-based sustained drug delivery for retina — Axpaxli (wet AMD) and Dextenza.
Hydrogel depot technology for sustained ocular drug delivery. Axpaxli (axitinib intravitreal implant) in late-stage trials for wet AMD; Dextenza commercial for ocular surgery/post-op.
HQ: Bedford, MA, USA